New TB regiment set to be tested

The Global Alliance for TB Drug Development has announced the launch of a clinical trial to test a novel tuberculosis regiment that may be able to treat both drug-sensitive and multidrug-resistant tuberculosis using a single three-drug combination.

The announcement was made on the eve of the 41st Union World Conference on Lung Health in Berlin, Germany. If successful, the treatment could reduce treatment duration on MDR-TB from two years to six months or less, according to

The Phase II trial, called New Combination 1 or NC001, will test the drug candidates moxifloxacin and PA-824 with pyrazinamide. The treatment has the potential to shorten treatment time for nearly all tuberculosis patients and to give similar treatment to DS-TB and MDR-TB.

The new compounds are being developed by TB Alliance, which is partnering with Bayer HealthCare AG, reports. The trials will begin in two centers in South Africa, which has one of the highest TB burdens.

TB kills nearly 2 million people each year and is the leading killer of those infected with HIV/AIDS. Since the current treatment process is so long, many patients are not able to finish treatment, which leads to drug resistance.

“We need more than a new drug to eradicate TB - we need entirely new regimens of TB drugs,” Mel Spigelman, president and CEO of the TB Alliance, said, according to “The potential to offer a single regimen to treat both drug-sensitive and multidrug-resistant TB represents a monumental advance in the treatment of patients worldwide, and a tremendous step toward simplifying the delivery of TB treatment globally.”